EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
Volume 2.75M
Average 0.95M
EYPT EBITDA Margin
EBITDA as a percentage of revenue.
EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -12104.3%
EBITDA Margin was -12104.3% in Q1 FY2026, down 11921.5 pp from a year earlier. On a trailing-twelve-month basis it was -3415.1%, down 3156.5 pp year over year. Over 3 fiscal years it narrowed by 497.7 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 10 analysts of -14995.5% for the fiscal year ending Dec 2026, down from -731.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -12104.3%-2771.6 pp QoQ
- Last fiscal yearDec 2025
- -731.1%-432.4 pp YoY
- LTMMar 2026
- -3415.1%-3156.5 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -731.1%
- Year-over-year change
- -432.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -731.1% | -432.4pp |
| FY2024 | 2024-12-31 | -298.6% | -148.7pp |
| FY2023 | 2023-12-31 | -149.9% | +83.4pp |
| FY2022 | 2022-12-31 | -233.4% | -97.6pp |
| FY2021 | 2021-12-31 | -135.8% | — |
EBITDA Margin vs competitors
How EYPT compares with its peers on the latest reported figures
- EYPT's LTM Mar 2026 EBITDA Margin of -3415.1% is the 5th highest of the 7 companies compared; the peer median is -283.6%.
- Its year-over-year change of -3156.5 pp is the lowest of 7, against a peer median of +299.2 pp.
- Over three fiscal years its change of -497.7 pp compares with a peer median of +208.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 46.0% | +315.4 pp | +147.4 pp | |
SEPNSepterna, Inc. | LTM Sep 2026 | -59.3% | +282.9 pp | — |
| FY2025 | -159.2% | +144.1 pp | +269.3 pp | |
| LTM Mar 2026 | -408.0% | -146.3 pp | — | |
| LTM Mar 2026 | -3415.1% | -3156.5 pp | -497.7 pp | |
| LTM Mar 2026 | -4732.2% | +354.4 pp | — | |
| LTM Mar 2026 | -16919.8% | +35407.7 pp | — | |
| FY2025 | — | — | — | |
BCAXBicara Therapeutics Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding EYPT) | -283.6% | +299.2 pp | +208.3 pp | |
Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 36.94M | 41.4M | 46.02M | 43.27M | 31.37M |
| Cost of Revenue | 8.18M | 8.33M | 4.63M | 3.71M | 2.07M |
| Gross Profit | 28.76M | 33.08M | 41.39M | 39.56M | 29.31M |
| Gross Margin | 77.9% | 79.9% | 89.9% | 91.4% | 93.4% |
| Research & Development | 28.5M | 49.64M | 64.66M | 132.93M | 221.04M |
| Selling, General & Admin | 53.08M | 60.32M | 51.79M | 52.49M | 51.7M |
| Operating Expenses | 84.04M | 132.72M | 116.45M | 185.42M | 272.74M |
| Depreciation & Amortization | 2.77M | 2.45M | 464K | 1.54M | 2.31M |
| EBITDA | (50.15M) | (96.62M) | (69M) | (129.23M) | (229.34M) |
| EBITDA Margin | -135.8% | -233.4% | -149.9% | -298.6% | -731.1% |
| Operating Income | (55.28M) | (99.64M) | (75.07M) | (145.85M) | (243.43M) |
| Operating Margin | -149.6% | -240.6% | -163.1% | -337.1% | -776.0% |
| Interest Income | 292K | 2.13M | 6.95M | 15.09M | 11.75M |
| Interest Expense | 5.5M | 3.19M | 1.25M | 14K | (33K) |
| Other Income / Expenses | (3.14M) | (2.62M) | 4.36M | 15.07M | 11.75M |
| Income Before Tax | (58.42M) | (102.25M) | (70.71M) | (130.78M) | (231.68M) |
| Pre-Tax Margin | -158.1% | -247.0% | -153.7% | -302.2% | -738.5% |
| Income Tax Expense | 0 | 0 | 83K | 90K | 279K |
| Net Income | (58.42M) | (102.25M) | (70.8M) | (130.87M) | (231.96M) |
| Net Margin | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% |
| EPS (Basic) | (2.03) | (2.74) | (1.82) | (2.32) | (3.17) |
| EPS (Diluted) | (2.03) | (2.74) | (1.82) | (2.32) | (3.17) |
| Weighted Avg Shares | 28.76M | 37.32M | 38.9M | 56.3M | 73.25M |
| Weighted Avg Shares (Diluted) | 28.76M | 37.32M | 38.9M | 56.3M | 73.25M |
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.